Skip to main content

Table 2 Summary of clinical trials using periodontal ligament (PDL)-derived cells

From: Promising advances in clinical trials of dental tissue-derived cell-based regenerative medicine

ReferencesRegistration IDConditionStudy designPatients (teeth), test/controlInterventionsFollow-upOutcomesRisk of bias assessments
TestControl
Feng et al. [25]NRPeriodontal diseasesCase series3 (16)PDL progenitor + hydroxylapatite (Calcitite®)3, 6, 12, 26, 32, 42, 72 monthsPPD and CAL were decreased and gingival recession was increased.
Chen et al. 2016 [26]NCT01357785Periodontal diseasesRCT30 (41), 20/21PDLSC sheets + DBBM (Bio-oss®)Bio-oss®2 weeks, 3 months, 6 months, 1 yearNo statistically significant differences were found for the increased CAL, PPD, or alveolar bone height between the test group and the control group.Low
Iwata et al. [27]UMIN000005027Periodontal diseasesCase series10 (10)PDL-derived cell sheet + beta-tricalcium phosphate (β-TCP) granules3 months, 6 monthsPPD, CAL, and radiographic bone height were improved in all cases.
  1. NR not reported, RCT randomized controlled trial, PPD periodontal probing depth, CAL clinical attachment level, PDLSC periodontal ligament stem cells, DBBM deproteinized bovine bone mineral